Market capitalization | $363.41m |
Enterprise Value | $328.67m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 288.31 |
EV/Sales (TTM) EV/Sales | 1.97 |
P/S ratio (TTM) P/S ratio | 2.18 |
P/B ratio (TTM) P/B ratio | 1.73 |
Revenue growth (TTM) Revenue growth | 2.94% |
Revenue (TTM) Revenue | $166.88m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a Anika Therapeutics, Inc. forecast:
3 Analysts have issued a Anika Therapeutics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 167 167 |
3%
3%
|
|
Gross Profit | 103 103 |
5%
5%
|
|
EBITDA | -1.88 -1.88 |
85%
85%
|
EBIT (Operating Income) EBIT | -14 -14 |
51%
51%
|
Net Profit | -74 -74 |
235%
235%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
Head office | United States |
CEO | Cheryl Blanchard |
Employees | 357 |
Founded | 1992 |
Website | www.anika.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.